Curium comments on supply challenges for Eclipse clinical trial

By staff writers

March 20, 2023 -- Nuclear medicine company Curium confirmed in a recent statement that it doesn't expect supply challenges of its lutetium-177 (Lu-177) prostate-specific membrane antigen (PSMA) with 3-iodo-D-tyrosine (I&T) for the company's Eclipse phase III clinical trial.

The trial is ongoing in the U.S., France, Spain, and Italy. Since patient enrollment started in March 2022, the trial has experienced what the company says is "reliable and uninterrupted" supply of the radiotherapy.

Eclipse is a phase III, multicenter, open-label, randomized clinical trial comparing the safety and efficacy of Lu-177 PSMA-I&T versus hormone therapy in patients with metastatic castration-resistant prostate cancer.

Copyright © 2023

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking